Based
on Pfizer’s Lyrica patent, Korean courts granted preliminary injunctions for
patent infringement against two Korean pharmaceutical companies in 2015.
Furthermore,
in June 2017, the Seoul Central District court awarded Pfizer damage
compensations for pregabalin patent infringement. However, the Korean Court did
not grant injunction against Korean companies who sell generic products with
off-labels.
The
active ingredient of Lyrica is pregabalin that is a known chemical compound and
a derivative of GABA (gamma-aminobutyirc acid). Further, the pharmacological
effect of pregabalin is known as a depressive neurotransmitter and has been
sold as an anti-convulgent drug for a long time. Pfizer discovered a new
medicinal use of pregabalin. The subject Korean Patent No. 491282 is directed
to a new use of pregabalin for treating pain. It is a second use invention that
is one of the main indications of Lyrica.
Korean
companies challenged validity of the subject patent on the ground that the new use
of pregabalin for treating pain can be anticipated or is obvious over the prior
art. They alleged that the pain killing effect might be in the scope of anticipation
of an ordinary skilled person because the prior art discloses the compound and
its neurotransmitter depressing effect. Also, the blocking of certain
neurotransmitter flow may be correlated with anti-pain effect. The IPT of KIPO
and the Patent Court, the Supreme Court, however, maintained the patent by
rejecting non-obviousness challenge.
After
validity challenge was failed, Korean generic companies restricted indications
of their label only to anti-convulgent. They carved out pain killing use from
their labels.
The
patentee argued that the change of label is not enough to avoid patent
infringement liability because the sale of generic drugs has slightly dropped
or never changed even after the carved-out pain treatment indication from the
labels. Accordingly, the generic companies shall be liable for the patent
infringement of their continued sale after the label change.
The
Seoul Central District Court did not agree with the patentee’s argument. The
court held that the patent is directed to a second use invention and without
indication of the claimed use, there is no patent infringement.
The
Seoul Central District Court only awarded the patentee damage compensation
based on the sale before the label change – carved-out claimed indication from
the generic’s labels. Pfizer appealed to the Patent Court and the off-label
case of pregabalin is still pending.